7,713 Shares in Grail, Inc. (NASDAQ:GRAL) Purchased by Bamco Inc. NY

Bamco Inc. NY purchased a new stake in Grail, Inc. (NASDAQ:GRAL - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 7,713 shares of the company's stock, valued at approximately $138,000.

A number of other large investors have also recently bought and sold shares of the business. FNY Investment Advisers LLC purchased a new position in shares of Grail during the fourth quarter worth about $26,000. State of Tennessee Department of Treasury acquired a new position in shares of Grail in the fourth quarter valued at approximately $28,000. Lindbrook Capital LLC purchased a new stake in shares of Grail during the fourth quarter worth approximately $28,000. Sterling Capital Management LLC acquired a new stake in shares of Grail during the fourth quarter worth $29,000. Finally, Wellington Shields Capital Management LLC acquired a new position in Grail in the 4th quarter valued at $33,000.

Grail Stock Down 2.5 %

GRAL stock traded down $0.90 during trading on Friday, reaching $35.20. 878,412 shares of the company were exchanged, compared to its average volume of 1,223,599. Grail, Inc. has a 52-week low of $12.33 and a 52-week high of $63.99. The stock's 50 day moving average price is $29.67 and its 200 day moving average price is $25.56.

Grail (NASDAQ:GRAL - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The company reported ($1.86) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.41) by $2.55. The firm had revenue of $38.25 million for the quarter, compared to analyst estimates of $35.33 million. On average, research analysts expect that Grail, Inc. will post -15.15 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Canaccord Genuity Group started coverage on shares of Grail in a research note on Monday, April 21st. They issued a "buy" rating and a $32.00 target price for the company. Morgan Stanley boosted their target price on Grail from $16.00 to $20.00 and gave the stock an "equal weight" rating in a research report on Tuesday, March 18th.

Insider Buying and Selling

In related news, CEO Robert P. Ragusa sold 94,035 shares of the company's stock in a transaction that occurred on Friday, May 2nd. The stock was sold at an average price of $33.93, for a total value of $3,190,607.55. Following the sale, the chief executive officer now owns 734,627 shares of the company's stock, valued at approximately $24,925,894.11. This represents a 11.35 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, President Joshua J. Ofman sold 2,109 shares of the business's stock in a transaction on Friday, March 7th. The stock was sold at an average price of $31.20, for a total value of $65,800.80. Following the completion of the transaction, the president now directly owns 559,673 shares of the company's stock, valued at approximately $17,461,797.60. This trade represents a 0.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 194,948 shares of company stock worth $6,583,130 in the last three months.

Grail Company Profile

GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.